Complete molecular remission in chronic myelogenous leukemia after imatinib therapy

被引：33

作者：

Barbany, G

Höglund, M

Simonsson, B

机构：

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2002年 / 347卷 / 07期

关键词：

D O I：

10.1056/NEJM200208153470719

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：539 / 540

页数：2

相关论文

共 5 条

[1] Barbany G, 2000, CLIN CHEM, V46, P913
[2] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
Druker, BJ
Sawyers, CL
Kantarjian, H
Resta, DJ
Reese, SF
Ford, JM
Capdeville, R
Talpaz, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1038 - 1042
[3] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker, BJ
Talpaz, M
Resta, DJ
Peng, B
Buchdunger, E
Ford, JM
Lydon, NB
Kantarjian, H
Capdeville, R
Ohno-Jones, S
Sawyers, CL
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1031 - 1037
[4] Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
Sawyers, CL
[J]. SEMINARS IN HEMATOLOGY, 2001, 38 (03) : 15 - 21
[5] Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction
Stentoft, J
Pallisgaard, N
Kjeldsen, E
Holm, MS
Nielsen, JL
Hokland, P
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2001, 67 (5-6) : 302 - 308